AorTech looks to new CEO (Chief Executive Officer) and restructure for stability
This article was originally published in Clinica
Executive Summary
AorTech is bidding to put recent disappointments behind it - trial delays for its polyurethane trileaflet heart valve and the slow progress in the deal to buy Becton Dickinson's critical care division (see Clinica No 1010, p 19) - with the appointment of a new CEO, Bill Strachan. Mr Strachan, formerly with Eli Lilly before moving to Johnson & Johnson where he spent 24 years, will be asked to "redress the fortunes" of the Bellshill, Scotland company, said chairman Eddie McDaid, who had additionally assumed CEO responsibilities pending a permanent appointee to the role.